se of Blood Product to deliver drugs in treatment of gum diseases

Phase 3

Completed

• Conditions: Health Condition 1: K053- Chronic periodontitis

• Registration Number: CTRI/2023/01/048659
• Lead Sponsor: Thamaraiselvan Murugan

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2023-03-18
• Last Update Posted: 26 June 2023

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 79

Inclusion Criteria

Patient selection was done according to the 2017 World Work­ shop on the Classification of Periodontal and Peri­Implant Diseases and Conditions. Patients with Stage II Grade B peri­odontitis (moderate periodontitis) were included. Patients having a minimum of 2 sites with probing depth (PD) > 5 mm and clinical attachment loss (CAL) >4 mm with horizontal bone loss at 2 different quadrants, and requiring non­surgical treat­ment were considered as eligible for the study.

Exclusion Criteria

Patients with habits, like smoking, tobacco chewing or alcohol consumption, having uncontrolled diabetes, hyper­ tension or immunocompromised conditions, pregnant women or lactating mothers, non­compliant or physically challenged people, and those who were not able to main­ tain oral hygiene or be followed up at a recall visit

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Probing Depth (PD), Clinical Attachment Level (CAL), Gingival Index (GI), plaque Index (PI),Timepoint: Baseline (BL), 6th week, 12th week

Secondary Outcome Measures

Name	Time	Method
Salivary Glutathione levels, Salivary collagenase levels, p.gingivalis levelsTimepoint: Baseline (BL), 6th week, 12th week